Navigation Links
In First of Its Kind Setup, MedeFile Interfacing Directly with Physician's Office
Date:6/1/2010

BOCA RATON, Fla., June 1 /PRNewswire-FirstCall/ -- In a singular development in the field of portable electronic medical records management, MedeFile International, Inc. (OTC Bulletin Board: MDFI.OB), already an industry leader in Personal Health Records, has announced the signing of an unprecedented agreement with Dr. Jeffrey Stein, M.D., in which the Doctor and Registered Nurse in the practice will be incorporating MedeFile's PHR technology into its new EMR records system, interfacing directly with MedeFile's platform, thus providing subscribing patients with immediate access to their secure, comprehensive and vital health and medical information.  

In anticipation of the launch of this revolutionary program, Dr. Stein's office has been offering the MedeFile PHR package, on a pre-order basis, to the practice's patients. When offered the unparalleled opportunity to consolidate, coordinate and safely store and access their lifelong health history through their primary care physician, an overwhelmingly positive response is being garnered. This first-of-its-kind program allows MedeFile the ability to interface directly with Dr. Stein's EMR solution in order to provide his patients with the most up-to-date information on their healthcare, essentially in real time.  

"This program is just tremendous for my practice and my patients, many of whom are snow birds," said Dr. Stein.  "They travel frequently, sometimes far from home, and MedeFile's innovations will empower them by giving them total control of and worldwide access to their medical information.  Not only can they now access my office records, anytime, anywhere, but participating members can also access any of their other provider's information in their MedeFile as well."  Dr. Stein added, "I've been waiting for this technology to become available in this capacity for quite some time, as I believe it is the future of healthcare. MedeFile had demonstrated such integrity and excellence that I am confident my patients will feel the same way as I do about the MedeFile system – that it is invaluable in maintaining one's health and in affecting positive medical outcomes."

Milton Hauser, CEO of MedeFile, was inspired. "This venture is merely the beginning. The incredible response from Dr. Stein's patients speaks to the fact that having the stamp of approval from their doctor is really a tipping point in people making the decision to choose EMR. We will continue to develop and pursue synergistic relationships with private practices, with the goal of providing as many people as possible with anytime anywhere access to their medical records."

About MedeFile International, Inc.

Headquartered in South Florida, MedeFile has a proprietary system for gathering and digitizing medical records so that individuals can have a comprehensive record of all of their medical visits. MedeFile's primary product is the MedeFile system, a highly secure system for gathering and maintaining medical records. The MedeFile system is designed to gather all of its members' actual medical records and create a single, comprehensive medical record that is accessible 24 hours a day, seven days a week. For more information about MedeFile and its annual subscription-based programs, please visit www.medefile.com

Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of MedeFile could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the Company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates, and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, and such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, review our SEC filings.

Contact:  Investors, 1-888-241-0800, investor@medefile.com


'/>"/>
SOURCE MedeFile International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):